{"id":"W2054399435","doi":"10.1016/s1873-9954(07)70080-0","title":"P068 NATALIZUMAB MAINTAINS REMISSION FOR 2 YEARS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE AND IN THOSE WITH PRIOR INFLIXIMAB EXPOSURE: RESULTS FROM AN OPEN-LABEL EXTENSION STUDY","year":2007,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis Supplements","topic":"Immunodeficiency and Autoimmune Disorders","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Natalizumab; Infliximab; Crohn's disease; Medicine; Open label; Disease; Internal medicine; Extension (predicate logic); Gastroenterology; Adverse effect; Computer science","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001272048,0.0005230488,0.001267262,0.0002580209,0.0003513992,0.0005817225,0.0003909962,0.000883327,0.001565311],"category_scores_gemma":[0.001506161,0.0002514211,0.001059702,0.0002751865,0.000462957,0.0006633796,0.0002589629,0.001536137,0.0003896597],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002388908,"about_ca_system_score_gemma":0.0002705452,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005421387,"about_ca_topic_score_gemma":0.001049855,"domain_scores_codex":[0.9993467,0.0003153303,0.00006049793,0.0000803451,0.00008506731,0.0001121151],"domain_scores_gemma":[0.998898,0.0002854004,0.000268057,0.0001089202,0.00005964259,0.0003798937],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.705733,0.02516197,0.05390614,0.0007865106,0.002432937,0.0008593291,0.0004896452,0.0005856148,0.03580038,0.0001257265,0.00197906,0.1721396],"study_design_scores_gemma":[0.2056981,0.4950891,0.2888364,0.0001046971,0.001649291,0.00149035,0.0001729726,0.0009015597,0.002713887,0.0001637835,0.003114172,0.00006559552],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.996524,0.002330815,0.00008874228,0.0001529363,0.00003692142,0.00009257618,0.0001690993,0.00001492103,0.0005899793],"genre_scores_gemma":[0.998069,0.0007184251,0.0001969653,0.0001902434,0.00009527763,0.0000827204,0.0003025244,0.000003587861,0.0003412876],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001565311,"threshold_uncertainty_score":0.006727338,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0167947458870927,"score_gpt":0.2927308397466874,"score_spread":0.2759360938595947,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}